Chromadex Corp (NASDAQ: CDXC) has a price-to-earnings ratio of 300.85x that is above its average ratio. Additionally, the 36-month beta value for CDXC is 2.22. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CDXC is 48.35M and currently, short sellers hold a 4.37% ratio of that float. The average trading volume of CDXC on February 19, 2025 was 506.98K shares.
CDXC) stock’s latest price update
Chromadex Corp (NASDAQ: CDXC)’s stock price has decreased by -3.79 compared to its previous closing price of 5.91. However, the company has seen a 3.38% increase in its stock price over the last five trading sessions. businesswire.com reported 2025-01-06 that LOS ANGELES–(BUSINESS WIRE)—- $CDXC #ChromaDex–ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, today announced that it will participate in a webcasted company presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025. The company presentation will take place at 12:00 p.m. ET on Monday, January 13, 2025. The webcast can be accessed directly at https://lytham.
CDXC’s Market Performance
Chromadex Corp (CDXC) has experienced a 3.38% rise in stock performance for the past week, with a -4.27% drop in the past month, and a -21.03% drop in the past quarter. The volatility ratio for the week is 3.77%, and the volatility levels for the past 30 days are at 4.33% for CDXC. The simple moving average for the past 20 days is -0.63% for CDXC’s stock, with a 32.62% simple moving average for the past 200 days.
Analysts’ Opinion of CDXC
B. Riley Securities, on the other hand, stated in their research note that they expect to see CDXC reach a price target of $2.40, previously predicting the price at $6. The rating they have provided for CDXC stocks is “Neutral” according to the report published on August 11th, 2022.
ROTH Capital gave a rating of “Buy” to CDXC, setting the target price at $7 in the report published on March 08th of the previous year.
CDXC Trading at -1.31% from the 50-Day Moving Average
After a stumble in the market that brought CDXC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.69% of loss for the given period.
Volatility was left at 4.33%, however, over the last 30 days, the volatility rate increased by 3.77%, as shares sank -4.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.84% lower at present.
During the last 5 trading sessions, CDXC rose by +5.64%, which changed the moving average for the period of 200-days by +58.74% in comparison to the 20-day moving average, which settled at $5.73. In addition, Chromadex Corp saw 7.18% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CDXC starting from Jaksch Frank L Jr, who sale 37,161 shares at the price of $6.19 back on Dec 13 ’24. After this action, Jaksch Frank L Jr now owns 244,179 shares of Chromadex Corp, valued at $229,956 using the latest closing price.
Frank Jaksch Jr., the affiliate of Chromadex Corp, proposed sale 37,161 shares at $6.19 during a trade that took place back on Dec 13 ’24, which means that Frank Jaksch Jr. is holding shares at $229,961 based on the most recent closing price.
Stock Fundamentals for CDXC
Current profitability levels for the company are sitting at:
- 0.02 for the present operating margin
- 0.56 for the gross margin
The net margin for Chromadex Corp stands at 0.01. The total capital return value is set at 0.06. Equity return is now at value 4.82, with 2.70 for asset returns.
Based on Chromadex Corp (CDXC), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at 1.41.
Currently, EBITDA for the company is -3.89 million with net debt to EBITDA at -15.16. When we switch over and look at the enterprise to sales, we see a ratio of 4.04. The receivables turnover for the company is 14.23for trailing twelve months and the total asset turnover is 1.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.95.
Conclusion
In conclusion, Chromadex Corp (CDXC) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
